NCT01736813已完成不适用
Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial)
National Center for Tumor Diseases, Heidelberg1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent
研究概览
简要总结
The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth. The agent for the inhibition of CCR5 has already received FDA approval for treatment of HIV and has shown little side effects and toxicities even on long term treatment. Therefore CCR5-inhibition has the potential of providing non-toxic tumor growth inhibition.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •written informed consent (must be available before enrollment in the trial)
- •age ≥ 18 years
- •male or female patient with a history of treated metastatic stage IV colorectal cancer with liver metastases of the primary colorectal cancer
- •histologically confirmed liver metastasis of colorectal cancer with histologically confirmed CCR5 (C-C chemokine receptor type 5) expression in the tumor cells
- •expected survival of at least three months
- •Karnofsky performance status > 70 %
- •patients that have received current standard treatment options (progression or intolerance to oxaliplatin, irinotecan and 5-Fluorouracil with or without treatment combinations of cetuximab and/or bevacizumab or panitumumab)
- •no chemotherapy treatment within the last three weeks
- •within the last 2 weeks prior to study day 1 the following laboratory parameters, which should be within the ranges specified (or as deemed acceptable by trial investigator): absolute neutrophil count (ANC) ≥ 1000/mm3 (≥ 1.0 x 109/L), platelets ≥ 80.000/mm3 (≥ 80 x 109/L), creatinine Clearance limit as assessed by glomerular filtration rate > 60 mL/min/1.73m², ALT (alanine transaminase), AST (aspartate transaminase), and total bilirubin all ≤ 5.0 x ULN (upper limit normal)
- •able and willing to give valid written informed consent and to understand character and individual consequences of the clinical trial
- •if the patient is female, she must be of non-childbearing potential, or practice adequate contraception.
排除标准
- •Patients with severe kidney disorders (GFR of <30 mL/min/1.73m² and diagnosed kidney disease) or who are on hemodialysis. The patient requires concomitant chronic treatment with systemic corticosteroids or any other immunosuppressive agents. Topical or inhalational steroids are permitted.
- •Patients taking immunomodulatory medication (Type 1 interferons).
- •Use of any investigational or non-registered product (drug or vaccine) other than the study treatment
- •Patients with single metastatic lesions (intent to resect the metastasis)
- •Patients with metastatic colorectal cancer that have a drastic clinical progression (e.g. from Karnofsky performance 100% to 60%) within the last six weeks before screening cannot participate
- •The patient has a history of autoimmune disease.
- •The patient has a family history of congenital or hereditary immunodeficiency.
- •The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other chronic infections (HBV, HCV).or has another confirmed or suspected immunosuppressive or immunodeficient condition.
- •The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.
- •The patient has concurrent chronic severe medical problems (heart failure, uncontrolled diabetes, bleeding disorder etc.), unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
- •The patient has previous or concomitant malignancies at other sites, except effectively treated carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and is highly likely to have been cured.
- •For female patients: the patient is pregnant or lactating.
- •Women of childbearing potential: Refusal or inability to use effective means of contraception
- •History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
- •Participation in other clinical trials or observation period of competing trials, respectively
- •No subject will be allowed to enroll in this trial more than once.
研究组 & 干预措施
CCR5-inhibitor at 300 mg/bid
colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
干预措施: Maraviroc (Drug)
结局指标
主要结局
safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent
时间窗: after eight weeks of treatment
safety, tolerability and feasibility will be assessed after eight weeks of continuous intake of the CCR5-inhibitor. Safety measures include blood analyses (hematologic, liver function, renal function etc.) and the overall performance status of the patient. Especially infections and infection-related events are investigated.
次要结局
- Progression Free Survival(one year after eight weeks of treatment)
- Tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST)(after eight weeks of treatment)
- Tissue level responses of growth inhibition via the CCR5 axis(during the first four weeks of treatment)
- Overall survival(one year after eight weeks of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsKRAS WildtypeAfter Resection of Liver MetastasesColorectal CancerNCT01384994PD Dr. med. Volker Heinemann111
招募中
不适用
Advanced Therapies for Liver MetastasesPancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Liver MetastasisIPMN, PancreaticNCT04622423IRCCS San Raffaele625
已完成
3 期
Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only MetastasesLiver MetastasesColorectal CancerNCT02162563Dutch Colorectal Cancer Group530
已完成
1 期
Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00444041Austrian Society Of Surgical Oncology43
已完成
2 期
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter StudyColorectal Cancer With Non Resectable Hepatic MetastasisNCT01839877Federation Francophone de Cancerologie Digestive58